The amino acid L-glutamine has been shown to be important to numerous cells in the body. However, the routine measurement of glutamine in biological solutions is complicated by its relative instability, particularly at extremes of pH. We report a simple bacterial bioassay method for the estimation of glutamine, carried out at neutral pH, using an Escherichia coli that is specifically dependent on the presence of glutamine for replication. The assay is simple to perform and we have shown it to be highly reproducible. Furthermore, we observed significant correlation between the estimations of glutamine by the bioassay system and current methodologies. The levels of glutamine recorded were higher than by other methods. We also found that deproteinization and neutralization of samples allowed them to be stored at -70°C for up to 24 weeks without deterioration.
Additional key phrases: amino acids, high performance liquid chromatography
The amino acid L-glutamine (hereafter referred to as glutamine) has been shown to be relatively unstable in aqueous solutions, I particularly at extremes of pH 2 and is not always incorporated into commercially available amino acid standards because of its instability.' These properties have made the routine measurement of glutamine in biological solutions difficult. Current methods, used to measure a variety of amino acids, do not allow for the relative instability of glutamine, in that extremes of pH are used in the procedures. Hence glutamine estimation may not be quantitatively accurate." Quantification of glutamine by enzyme assay involves conversion of glutamine to glutamate,' the subsequent degradation of the product to~ ketoglutarate at pH 9.0,6 and the concomitant conversion of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). It is this change which is measured spectrophotometrically and is proportional to glutamine concentration. Automated amino acid analysers have also been developed, based on this enzyme assay.' Other methods, including high performance liquid chromatography (HPLC)8 and ion exchange chromatography? are not without their problems, and generally require acidified samples in analytical procedures.' More recently, HPLC has been tailored to specifically measure glutamine, but its widespread use in clinical biochemistry still requires careful preparative techniques and the use of multiple time-based controls within analyses containing large numbers of samples to compensate for the degeneration of glutamine.
Glutamine has been shown to be important to numerous cells in the body, both as an energy source via oxidation, and also as a precursor for purines and pyrimidines in nucleotide, and hence nucleic acid, synthesis. 10 There are many reports of lowered glutamine levels in both plasma and muscle following stress of various forms including surgery," burns, II major'? and minor!' infectious episodes, and acute exercise.lv" In an attempt to improve the accuracy of glutamine estimation in biological fluids, we have developed a simple bacterial bioassay using an Escherichia coli that is specifically dependent on the presence of glutamine for replication."
METHODS

Sample preparation
Blood samples, collected in lithium heparin, were immediately chilled on ice and centrifuged at 1200g for 5min in a Beckman TJ-6
Bacterial bioassay for L-glutarnine Initial studies The standard curve remained linear across the lower glutamine concentrations measured (0'03-0·25 mmol/L), and all deproteinized plasma samples and tissue extracts measured were within this range, due to dilution during sample preparation. In this linear region, the absorbance at 590 nm was directly proportional to the amount of glutamine present ( Fig. I ). Increasing the amount of bacteria added, from 25 ilL to 75 ilL of suspension, did not affect the dependence of absorbance on the concentration of glutamine over the linear portion of the standard curve ( Fig. I) . For plasma at 1·0 mol/L, deproteinized and prepared for analysis, coefficients of variation (n = 10) were 3·3% intra-assay and 4·5% inter-assay.
For the measurement of glutamine in the plasma of hospital patients, the administration of antibiotics to patients was a potential volumes were aliquoted into 96-well flat bottomed trays (Falcon, Becton Dickinson, USA) and the absorbance at 590 nM determined using a multi-well plate scanner (Multiskan Plus, Titertek, Finland). Glutamine in each plasma or tissue extract, set up concurrently, was estimated using the standard curve and the dilution factors incurred in preparation of the samples.
Bioassay
The measurement of glutamine depends on the absolute requirement for glutamine by E. coli YMCII (Coli Genetic Stock Centre, Department of Biology, Yale University, CT, USA). 16 This absolute requirement is confirmed by the lack of growth in control cultures where no glutamine is present. Recovery studies have shown, however, that the bacteria remain viable in the absence of glutamine. However, to control for the possibility of any transmutations, fresh cultures were grown monthly in Brain/Heart Infusion (BHI) Broth, from initial stock stored in glycerol at -70°C. Cultures were then plated onto BHI agar, single colony subcultured, sealed, and stored at 4"C. To obtain cultures in log phase of growth, a small number of colonies were resuspended in BHI Broth and grown at 37"C with shaking for approximately 4 h.
A standard curve of glutamine concentrations (0, 0,03, 0,06, 0,125, 0,25, O'5, 1·0 mmol/L [Sigma, St Louis, USA]) was prepared fresh for each assay in a total of 2 mL of medium consisting of 1·9 mL sterile double distilled H 20, 0'04mL 50% glucose, 0'04mL 50 4 and homogenized before being left on ice for 10min. In all cases, after centrifuging at 1200 g for 5 min as before, a measured volume of supernatant was collected and immediately neutralized to pH 7·0 with 20% (w/v) potassium hydroxide in O'5 mol/L triethanolamine. After leaving on ice for a further 10min, samples were centrifuged as before and the supernatant stored at -70"C until analysis. This procedure of sample deproteinization removed the potential of interference in the assay by most antibiotics (see results), haemolysis, lipaemia, and icterus.
confounding factor in the bioassay system. Only those antibiotics which act on Gram-negative bacteria needed to be considered. Testing the activity of 20 ilL of plasma containing gentamicin (15 Ilg/mL), tobramycin (15 Ilg/ml), amoxicillin (20 Ilg/mL), or ceftriaxone (100 Ilg/mL) individually or in various combinations, absorbed by antibiotic sensitivity disks, on a lawn of YMCII growing on agar, showed that the E. coli was sensitive to the antibiotics. However, the standard deproteinization and neutralization of the samples was sufficient to remove all antibacterial activity of the first three antibiotics, while the inhibitory activity of ceftriaxone was significantly diminished but not totally removed.
Since glutamine is known to be a precursor for nucleoside synthesis, we were initially concerned that nucleosides and nucleobases might enhance the growth of E. coli YMCII by bypassing the absolute requirement for glutamine. Dialysed plasma samples supplemented with physiological concentrations (0'01 mmol/L) of either hypoxanthine, uridine, adenosine, cytidine, or combinations of these, were tested (1) in the absence of glutamine; (2) in the presence of 1·0 mmol/L glutamine; (3) with 1·0 mmol/L glutamine added and then treated with asparaginase to remove glutamine. A small overestimation of glutamine concentration, in the order of 0·03-0,15 mrnol/L occurred on occasions. Further testing with a range of amino acids did not result in any significant overestimation of the glutamine concentration of deproteinized plasma samples.
Definitive studies
The effect of the deproteinization procedure on plasma glutamine concentration was assessed. Plasma samples were left in 15% HCI0 4 for a range of time periods (5-30min) before neutralization to pH 7·0. There was no deterioration of the plasma glutamine concentration over this period, as long as the reaction was carried out on ice.
A comparison of plasma glutamine concentrations was made for 22 samples of human plasma, simultaneously tested using the bioassay system and reverse phase HPLC (Waters 600). In the case of HPLC, on-column derivatization by O-phthalaldehyde preceded gradient elution of the plasma components, which were then quantitated using fluorescent spectroscopy (Hitachi FIOOO) and computer software (Waters: Baseline) (Perth Pathology Service, Midland, Western Australia). The methods were com-Ann Clin Biochem 1998: 35 pared by plotting the means of the paired measurements from the two methods against the difference between the paired measurements (r=0'792; P<O'OOI) (Fig. 2 ).17 Plasma glutamine concentrations estimated by the HPLC method were 59 (SD3)% of the glutamine concentration in the corresponding samples determined by the bioassay method.
A series of trials was carried out to test the stability of glutamine in stored samples of both plasma (P) and deproteinized plasma (DP). When samples were stored at -70°C as P or DP, less than 5% deterioration was recorded over 16 weeks or 24 weeks, respectively. After 30 weeks of storage, P samples had suffered 18% deterioration, and DP samples 10%. When stored at -20"C, DP samples deteriorated by less than 5% over 12 weeks, and had suffered a mean loss of 63% after 30 weeks.
Recovery experiments were performed using human plasma that had first been dialysed to remove all glutamine, and then spiked to a concentration of I rnmol/L before deproteinization and analysis in the routine manner. This yielded a recovery of 100 (SD5)% (standard deviation; n = 20). In addition, a range of samples were tested from both plasma and a variety of tissues, from a number of different species, including man, using the bioassay system (Table I) . There was a general trend towards higher glutamine concentrations when using this method. 
Glutamine concentrations (plasma: mmol] L. tissue: mmoljkg wet weight). estimated using the bioassay system, for plasma and a variety of organs and tissues [rom different species
One of the major problems to be addressed in the measurement of glutamine concentrations in biological fluids is the relative instability of this amino acid, particularly at extremes of pH. 2 Conventional methodologies use either acidic or basic conditions in the analytical procedures. We have developed a unique bioassay for the measurement of glutamine in biological solutions, mainly plasma and tissue extracts, which can be carried out at neutral pH. The assay is simple to perform and we have shown it to be highly reproducible. Our results suggested that over the range of glutamine concentrations measured in plasma and tissue extracts, the estimation of glutamine was not influenced by minor changes in the amount of E. coli added to the samples (Fig. 1) . Furthermore, we have no evidence to date that the assay is influenced by other components in the samples. The estimation of glutamine appeared to be only marginally affected by the addition of nuc1eosides or amino acids to the system, thus making it solely dependent on the presence of glutamine. Occasionally, antibiotics which may be present in the blood of patients, affected the growth of E. coli YMC 11, but the majority of antibacterial activity could be removed by the simple deproteinization and neutralization procedure.
The instability of glutamine means that it is rapidly lost from plasma and tissue samples at room temperature, and is still prone to considerable degradation if stored for prolonged periods, even at -70 n C. However, we found that deproteinization and neutralization of samples allowed them to be stored at -70°C for up to 24 weeks without deterioration. These findings are in agreement with previous work using HPLC methodology to determine the stability of glutamine concentration in stored plasma samples. IS We would recommend the routine use of deproteinization and neutralization procedures, as described here, for preservation of glutamine in biological fluids, even if prolonged storage is not anticipated.
Our results indicated a significant correlation between the estimations of glutamine by the bioassay system and HPLC methodology (Fig.  2 ). However, we tested a range of samples using the bioassay (Table 1 ) and generally the levels of glutamine recorded were higher than by other methods. This difference in values could not be due to the methods of sample preparation, since they have been used as standard procedures with other analytical methods.l'v'! Furthermore, our initial results suggested that the higher glutamine concentrations recorded could not be attributed to the non-specificity of the bioassay system, since nuc1eosides and amino acids caused only marginal over-estimation of glutamine concentration. Whether the results were due to the unique nature of the assay, circumventing the potential problems of sample degradation at extremes of pH which confound the estimation of glutamine, has yet to be fully investigated.
